Michael F Mac Lean Avidity Biosciences, Inc. (RNA) insider trading activity

Michael F Mac Lean is Chief Financial Officer of Avidity Biosciences, Inc.. Currently has a direct ownership of 63,832 shares of RNA, which is worth approximately $4.52 Million. The most recent transaction as insider was on Jan 07, 2026, when has been sold 1,974 shares (Common Stock) at a price of $72.23 per share, resulting in proceeds of $142,582. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 63.8K

3.0% 3M change

40.86% 12M change

Total Value Held $4.52 Million

Michael F MacLean Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 07 2026	SELL Open market or private sale	$142,582 $72.23 p/Share	1,974 Reduced 3.0%	63,832 Common Stock
Aug 06 2025	SELL Open market or private sale	$1,320,955 $42.73 p/Share	30,914 Reduced 31.96%	65,806 Common Stock
Mar 20 2025	SELL Open market or private sale	$246,461 $31.06 p/Share	7,935 Reduced 7.58%	96,720 Common Stock
Jan 21 2025	SELL Open market or private sale	$93,975 $28.59 p/Share	3,287 Reduced 3.05%	104,655 Common Stock
Jan 06 2025	BUY Grant, award, or other acquisition	-	25,000 Added 18.81%	107,942 Common Stock
Dec 18 2024	SELL Open market or private sale	$364,191 $32.66 p/Share	11,151 Reduced 11.85%	82,942 Common Stock
Nov 06 2024	SELL Open market or private sale	$4,851,335 $45.63 p/Share	106,319 Reduced 53.05%	94,093 Common Stock

Nov 06 2024	BUY Exercise of conversion of derivative security	$608,738 $7.7 p/Share	79,057 Added 42.27%	107,968 Common Stock
Sep 23 2024	SELL Open market or private sale	$506,440 $44.0 p/Share	11,510 Reduced 10.67%	96,355 Common Stock
Sep 19 2024	BUY Grant, award, or other acquisition	-	50,000 Added 29.18%	121,355 Common Stock
Jun 18 2024	SELL Open market or private sale	$439,351 $39.13 p/Share	11,228 Reduced 16.25%	57,865 Common Stock
Jun 17 2024	BUY Grant, award, or other acquisition	-	50,000 Added 37.63%	82,865 Common Stock
Jun 12 2024	SELL Open market or private sale	$3,723,631 $35.72 p/Share	104,245 Reduced 70.28%	44,093 Common Stock
Jun 12 2024	BUY Exercise of conversion of derivative security	$919,440 $8.82 p/Share	104,245 Added 41.27%	148,338 Common Stock
May 14 2024	SELL Open market or private sale	$2,121,000 $28.28 p/Share	75,000 Reduced 62.98%	44,093 Common Stock
May 14 2024	BUY Exercise of conversion of derivative security	$661,500 $8.82 p/Share	75,000 Added 38.64%	119,093 Common Stock
Mar 13 2024	SELL Open market or private sale	$980,800 $24.52 p/Share	40,000 Reduced 47.57%	44,093 Common Stock
Mar 13 2024	BUY Exercise of conversion of derivative security	$352,800 $8.82 p/Share	40,000 Added 32.23%	84,093 Common Stock
Jan 22 2024	SELL Open market or private sale	$16,370 $10.13 p/Share	1,616 Reduced 8.74%	16,884 Common Stock
Jan 20 2024	BUY Grant, award, or other acquisition	-	22,500 Added 45.26%	27,209 Common Stock
Jan 20 2023	BUY Grant, award, or other acquisition	-	18,500 Added 45.85%	21,852 Common Stock

Also insider at

VERV

Verve Therapeutics, Inc. Healthcare

MFM